section name header

Evidence summaries

Pregabalin for Chronic Prostatitis

Pregabalin appears not to improve CP/CPPS (chronic prostatitis/chronic pelvic pain syndrome) symptoms and appears to cause adverse effects in a large percentage of men. Level of evidence: "C"

The level of evidence is downgraded because of study quality and imprecise results (few patients).

Summary

A Cochrane review [Abstract] 1 included 1 study with a total of 324 subjects. For men who responded clinically ( 6-point improvement), there was no difference between the pregabalin (103/218; 47.2%) and placebo (38/106; 35.8%) arms (RR 1.32; 95% CI 0.99 to 1.76). There was less pain with a higher point improvement in the pregabalin group compared to the placebo group (4.2 points versus 1.7 points, respectively; mean difference (MD) -2.3 points; 95% CI -4.0 to -0.7 points).

Though 59% (191/324) of the patients developed side effects, no serious effects were experienced. There were significantly more neurologic side effects in the pregabalin group compared to the placebo group (38.5% (84/218) versus 22.6% (24/106), respectively; RR 1.7; 95% CI 1.15 to 2.51), and less pain in the pregabalin group than in the placebo group (17.4% (38/218) versus 33.3% (35/106), respectively; RR 0.53; 95% CI 0.36 to 0.78). However, no significant differences were seen between the pregabalin and placebo groups with regards to gastrointestinal disturbances (18.3% (40/218) versus 18.9% (20/106), respectively; RR 0.97; 95% CI 0.60 to 1.58), ocular/visual symptoms (6.9% (15/218) versus 2.8% (3/106), respectively; RR 2.43; 95% CI 0.72 to 8.22), and renal/genitourinary symptoms (5.5% (12/218) versus 1.9% (2/106), respectively; RR 3.03; 95% CI 0.67 to 13.79).

Clinical comments

Note

Date of latest search: 2012-05-29

    References

    • Aboumarzouk OM, Nelson RL. Pregabalin for chronic prostatitis. Cochrane Database Syst Rev 2012;8():CD009063. [PubMed]

Primary/Secondary Keywords